AAOpt 2023: A renaissance of new glaucoma treatment options

News
Article

As new treatment options continue to enter the glaucoma space, clinicians can provide the best care to each individual patient.

Mitch Ibach, OD, FAAO, with Vance Thompson Vision, caught up with Optometry Times®' during the 2023 American Academy of Optometry annual meeting in New Orleans to talk about some recent glaucoma treatment options.

Editor's note: This transcript has been edited for clarity.

Mitch Ibach, OD, FAAO:

Hi, I'm Mitch Ibach. I'm an optometrist with Vance Thompson Vision in Sioux Falls, South Dakota.

I'm here at Academy 2023 for Optometry in New Orleans. And one of the things I'm really excited about is the launch of Thea Pharma's Iyuzeh. This is the first and only FDA approved, commercially available, preservative free latanoprost for our patients.

If we think through the numbers, in the US, we have over 3 million Americans with glaucoma. We have over 16 Americans with diagnosed dry disease; I bet you can imagine that these can be intertwined. And we have patients with glaucoma who are being diagnosed, as well as being treated, who have pre existing and/or exacerbated dry eye because of topical glaucoma medications.

And so for my patients who are already struggling with dry eye disease, for maybe who are worried about preservatives going on to the eye—they've had some adverse events or side effects from previous topical glaucoma medications that they've taken. Or maybe it's a patient with neurotrophic keratoconjunctivitis, this can be a real win for some of these patients to be able to lessen their preservative load and their topical glaucoma medications.

One of the best and my favorite things about glaucoma treatments is we're kind of undergoing this renaissance of new treatment options and modalities for our patients. And so I always think of: treating glaucoma revolves around lowering interocular pressure. We have 4 main modalities: we have topical glaucoma drops, we have drug delivery devices, we have laser trabeculoplasty, and we have glaucoma surgeries. And really 3 of 4—maybe 4 of 4—of these categories continues to gain more options.

We have new drug delivery devices that are coming. We have new minimally invasive glaucoma surgeries. We have new topical glaucoma medications, as well.

And so all of these are really allowing practitioners more opportunities to customize the glaucoma treatment profile based on the patient that's in front of you.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Jessilin Quint, OD, MBA, FAAO, outlines her AOA's Optometry's Meeting 2025 presentation on nutrition and its impact on ocular health.
Carolyn Majcher, OD, FAAO, detailed a talk she gave alongside Mary Beth Yackey, OD, at Optometry's Meeting 2025.
Shelby Brogdon, OD, details opportunities for practices to answer the patient's concerns from the chair before they hit the internet for their contact lens needs.
Christi Closson, OD, FAAO, shares her excitement for the new Acuvue Oasys MAX 1-Day multifocal for astigmatism
Karen R. Hoffman, OD, shares how customizable scleral lenses can transform vision for patients with complex corneas, achieving 20/20 outcomes and enhanced comfort.
Janna Pham, OD, shares key takeaways from a corneal tomography session she presented alongside Travis Pfeifer, OD; and Matthew McGee, OD.
Jacob Lang, OD, FAAO, details early symptom relief demonstrated in as early as day 1 during AOA's Optometry's Meeting 2025.
When Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, began fitting scleral lenses 20 years ago, there was limited knowledge about conjunctival characteristics, scleral shape, and lens behavior.
Ioussifova details what sets Johnson & Johnson's new lens apart from the rest, which was launched at the American Optometric Association's Optometry's Meeting 2025.
Alongside Rachel Steele, OD, Rafieetary outlines what to look for in blurred disc margins and the importance of acting fast and sending patients to the ED when needed.
© 2025 MJH Life Sciences

All rights reserved.